The firm hiked its price target on shares of the St. Paul, MN-based medical technology company to $30 from $23.
Cardiovascular Systems has reached a "fundamental inflection point" following two consecutive strong quarters and after instating a new CEO, Leerink wrote in a note cited by TheFly.
The company's cost-control efforts could lead to profitability faster than expected, and the company could be cash-flow positive in the current fiscal 2017 year.
Separately, TheStreet Ratings team rates the stock as a "sell" with a ratings score of D.
Cardiovascular Systems's weaknesses include its disappointing return on equity and generally disappointing historical performance in the stock itself.
You can view the full analysis from the report here: CSII
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.